Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

[at noodls] – CARMIEL, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company’s phase I/II clinical … more

View todays social media effects on PLX

View the latest stocks trending across Twitter. Click to view dashboard

See who Protalix is hiring next, click here to view